This page has beta status

BMBS COST Action TD1205
Innovative methods in radiotherapy and radiosurgery using synchrotron radiation

Radiotherapy is one of the main treatment options for cancer patients. The physical properties of synchrotron-generated X-rays make them ideally suited for the design of new therapeutic approaches to treat both malignant and non-malignant diseases, in particular aggressive brain tumors. Centered around six multidisciplinary work groups, the COST teams will a) prepare for clinical trials in human patients preceded by, b) controlled trials in veterinary patients with spontaneous malignant tumours, c) preclinical studies in small animals, d) dosimetry, e) ethical aspects and patient care. SYRA3 will be an excellent coordination and communication tool for experienced scientists and Early Stage Researchers in the field of innovative radiotherapy & radiosurgery. International institutions and industrial partners are involved to apply standardization methods and for the dissemination/exploitation of results.

(Descriptions are provided by the Actions directly via e-COST.)


General Information*

Chair of the Action:

Dr Alberto BRAVIN (FR)

Vice Chair of the Action:

Dr Elisabeth SCHUELTKE (DE)

Science officer of the Action:

Dr Mafalda QUINTAS

Administrative officer of the Action:

Ms Aranzazu SANCHEZ

Downloads*

Action Fact Sheet

Download AFS as .RTF

Memorandum of Understanding

Download MoU as PDF

Websites*

Action website:

http://www.syra3.eu

* content provided by e-COST.
Data is synchronised once per night.

Tools

Last updated: 24 November 2012 top of page